These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
703 related articles for article (PubMed ID: 33004253)
1. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Miller RE; Leary A; Scott CL; Serra V; Lord CJ; Bowtell D; Chang DK; Garsed DW; Jonkers J; Ledermann JA; Nik-Zainal S; Ray-Coquard I; Shah SP; Matias-Guiu X; Swisher EM; Yates LR Ann Oncol; 2020 Dec; 31(12):1606-1622. PubMed ID: 33004253 [TBL] [Abstract][Full Text] [Related]
2. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773 [TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244 [TBL] [Abstract][Full Text] [Related]
4. Clinical assays for assessment of homologous recombination DNA repair deficiency. Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552 [TBL] [Abstract][Full Text] [Related]
6. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? Ngoi NYL; Tan DSP ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643 [TBL] [Abstract][Full Text] [Related]
7. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors. Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473 [TBL] [Abstract][Full Text] [Related]
8. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods]. Pfarr N; Merkelbach-Bruse S Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463 [TBL] [Abstract][Full Text] [Related]
9. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency? Gourley C; Miller RE; Hollis RL; Ledermann JA Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232 [TBL] [Abstract][Full Text] [Related]
10. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830 [TBL] [Abstract][Full Text] [Related]
11. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes. Pikkusaari S; Tumiati M; Virtanen A; Oikkonen J; Li Y; Perez-Villatoro F; Muranen T; Salko M; Huhtinen K; Kanerva A; Koskela H; Tapper J; Koivisto-Korander R; Joutsiniemi T; Haltia UM; Lassus H; Hautaniemi S; Färkkilä A; Hynninen J; Hietanen S; Carpén O; Kauppi L Clin Cancer Res; 2023 Aug; 29(16):3110-3123. PubMed ID: 36805632 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy. Rognoni C; Lorusso D; Costa F; Armeni P Adv Ther; 2024 Apr; 41(4):1385-1400. PubMed ID: 38329713 [TBL] [Abstract][Full Text] [Related]
13. Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Incorvaia L; Perez A; Marchetti C; Brando C; Gristina V; Cancelliere D; Pivetti A; Contino S; Di Giovanni E; Barraco N; Bono M; Giurintano A; Bazan Russo TD; Gottardo A; Cutaia S; Pedone E; Peri M; Corsini LR; Fanale D; Galvano A; Scambia G; Badalamenti G; Russo A; Bazan V Cancer Treat Rev; 2023 Dec; 121():102650. PubMed ID: 37939446 [TBL] [Abstract][Full Text] [Related]
14. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631 [TBL] [Abstract][Full Text] [Related]
16. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy. Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473 [TBL] [Abstract][Full Text] [Related]
17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting. Rabban JT; Chen LM; Devine WP Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159 [TBL] [Abstract][Full Text] [Related]
20. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency. Yuan P; Ma N; Xu B Med Res Rev; 2024 Nov; 44(6):2774-2792. PubMed ID: 38922930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]